452 related articles for article (PubMed ID: 23755755)
21. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.
Jermany J; Branson J; Schmouder R; Guillaume M; Rordorf C
J Clin Pharmacol; 2005 Oct; 45(10):1172-8. PubMed ID: 16172182
[TBL] [Abstract][Full Text] [Related]
22. Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.
Chang MC; Uang BJ; Tsai CY; Wu HL; Lin BR; Lee CS; Chen YJ; Chang CH; Tsai YL; Kao CJ; Jeng JH
Br J Pharmacol; 2007 Sep; 152(1):73-82. PubMed ID: 17641677
[TBL] [Abstract][Full Text] [Related]
23. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers.
Hinz B; Cheremina O; Besz D; Zlotnick S; Brune K
Int J Clin Pharmacol Ther; 2008 Apr; 46(4):180-6. PubMed ID: 18397691
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods.
Kovács EG; Katona É; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Édes I; Muszbek L
Thromb Res; 2014 May; 133(5):811-6. PubMed ID: 24207016
[TBL] [Abstract][Full Text] [Related]
25. Comparison of aspirin and indobufen in healthy volunteers.
Lee JY; Sung KC; Choi HI
Platelets; 2016; 27(2):105-9. PubMed ID: 26083594
[TBL] [Abstract][Full Text] [Related]
26. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
Patrick J; Dillaha L; Armas D; Sessa WC
Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
[TBL] [Abstract][Full Text] [Related]
27. Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions.
Yokoyama H; Yaguchi T; Suzuki Y; Tokuoka K; Watanabe M; Kitagawa Y; Yamada Y
Biol Pharm Bull; 2012; 35(12):2112-8. PubMed ID: 23047244
[TBL] [Abstract][Full Text] [Related]
28. Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects.
Polzin A; Richter S; Schrör K; Rassaf T; Merx MW; Kelm M; Hohlfeld T; Zeus T
Thromb Haemost; 2015 Jul; 114(1):87-95. PubMed ID: 25789542
[TBL] [Abstract][Full Text] [Related]
29. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016).
Corazzi T; Leone M; Maucci R; Corazzi L; Gresele P
J Pharmacol Exp Ther; 2005 Dec; 315(3):1331-7. PubMed ID: 16144976
[TBL] [Abstract][Full Text] [Related]
30. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
31. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.
Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T
Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188
[TBL] [Abstract][Full Text] [Related]
32. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
[TBL] [Abstract][Full Text] [Related]
33. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals.
Kovács EG; Katona E; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Edes I; Muszbek L
Thromb Res; 2013 Apr; 131(4):320-4. PubMed ID: 23422285
[TBL] [Abstract][Full Text] [Related]
34. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B
Gurbel PA; Bliden KP; Tantry US
J Thromb Thrombolysis; 2021 Feb; 51(2):260-264. PubMed ID: 33170486
[TBL] [Abstract][Full Text] [Related]
35. Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats.
Akagi Y; Nio Y; Shimada S; Aoyama T
Biol Pharm Bull; 2011; 34(2):233-7. PubMed ID: 21415533
[TBL] [Abstract][Full Text] [Related]
36. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies.
Crescente M; Jessen G; Momi S; Höltje HD; Gresele P; Cerletti C; de Gaetano G
Thromb Haemost; 2009 Aug; 102(2):336-46. PubMed ID: 19652885
[TBL] [Abstract][Full Text] [Related]
37. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
Meek IL; Vonkeman HE; Kasemier J; Movig KL; van de Laar MA
Eur J Clin Pharmacol; 2013 Mar; 69(3):365-71. PubMed ID: 22890587
[TBL] [Abstract][Full Text] [Related]
38. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
39. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings.
Crescente M; Cerletti C; de Gaetano G
Thromb Haemost; 2007 Jun; 97(6):1054-6. PubMed ID: 17549313
[No Abstract] [Full Text] [Related]
40. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans.
de la Cruz JP; Guerrero A; González-Correa JA; Márquez E; Nacle I; Sánchez de la Cuesta F
Eur J Clin Pharmacol; 2002 Jan; 57(11):775-80. PubMed ID: 11871383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
